Anticipating possible policy uses of addiction neuroscience research

References

• Ambermoon P, Carter A, Hall W, Dissanayaka N, O'Sullivan J. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: Evidence and implications for the addictions field. Addiction 2011; 106: 283–293
   PubMed Web of Science ®Google Scholar
• Ashcroft R, Campbell A, Capps B. Ethical aspects of developments in neuroscience and drug addiction. Drugs and the future: Brain science, addiction and society, D Nutt, T Robbins, G Stimson. Academic Press, London 2007; 439–466
   Google Scholar
• Babor T, Miller P, Edwards G. Vested interests, addiction research and public policy. Addiction 2010; 105: 4–5
   PubMed Web of Science ®Google Scholar
• Bachman JG, Wadsworth KN, O'Malley PM, Johnston LD, Schulenberg J. Smoking, drinking, and drug use in young adulthood: The impacts of new freedoms and new responsibilities. Lawrence Erlbaum, Mahwah, NJ 1997
   Google Scholar
• Ball D. Addiction science and its genetics. Addiction 2008; 103: 360–367
   PubMed Web of Science ®Google Scholar
• Baltuch GH, Stern MB. Deep brain stimulation for Parkinson's disease. Informa Healthcare, New York 2007
   Google Scholar
• Bauer R, Pohl S, Klosterkotter J, Kuhn J. Deep brain stimulation in the context of addiction – A literature-based systematic evaluation. Fortschritte der Neurologie-Psychiatrie 2008; 76: 396–401
   PubMed Web of Science ®Google Scholar
• Benabid AL, Pollak P, Seigneuret E, Hoffmann D, Gay E, Perret J. Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochirurgica Supplementum 1993; 58: 39–44
   PubMedGoogle Scholar
• Brandt AM. The cigarette century. Basic Books, Atlanta, GA 2007
   Google Scholar
• Caplan A. Denying autonomy in order to create it: The paradox of forcing treatment upon addicts. Addiction 2008; 103: 1919–1921
   PubMed Web of Science ®Google Scholar
• Carter A, Ambermoon P, Hall W. Drug-induced impulse control disorders: A prospectus for neuroethical analysis. Neuroethics 2011; 4: 91–102
   Web of Science ®Google Scholar
• Carter A, Bell E, Racine E, Hall W. Ethical issues raised by proposals to treat addiction using deep brain stimulation. Neuroethics 2011; 4: 129–142
   Web of Science ®Google Scholar
• Carter A, Hall W. Proposals to trial deep brain stimulation to treat addiction are premature. Addiction 2011; 106: 235–237
   PubMed Web of Science ®Google Scholar
• Carter A, Hall W. Addiction neuroethics: The promises and perils of neuroscience research on addiction. Cambridge University Press, London 2012
   Google Scholar
• Collins F. Medical and societal consequences of the Human Genome Project. New England Journal of Medicine 1999; 341: 28–37
   PubMed Web of Science ®Google Scholar
• Courtwright D. The NIDA brain-disease paradigm: History, resistance, and spinoffs. BioSocieties 2010; 5: 137–147
   Web of Science ®Google Scholar
• Dackis C, O'Brien C. Neurobiology of addiction: Treatment and public policy ramifications. Nature Neuroscience 2005; 8: 1431–1436
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. The Lancet 2012; 379: 55–70
   PubMed Web of Science ®Google Scholar
• Doran CM, Hall WD, Shakeshaft AP, Vos T, Cobiac LJ. Alcohol policy reform in Australia: What can we learn from the evidence. Medical Journal of Australia 2010; 192: 468–470
   PubMed Web of Science ®Google Scholar
• FDA. (2009). FDA approves humanitarian device exemption for deep brain stimulator for severe obsessive-compulsive disorder. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149529.htm
   Google Scholar
• Fergusson DM, Boden JM, Horwood LJ. The developmental antecedents of illicit drug use: Evidence from a 25-year longitudinal study. Drug and Alcohol Dependence 2008; 96: 165–177
   PubMed Web of Science ®Google Scholar
• Gartner CE, Barendregt JJ, Hall W. Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction 2009; 104: 118–126
   PubMed Web of Science ®Google Scholar
• Gerstein DR, Harwood HJ. Treating drug problems (Volume 1). A study of effectiveness and financing of public and private drug treatment systems. Institute of Medicine, National Academy Press, Washington, DC 1990
   Google Scholar
• Gundle KR, Dingel MJ, Koenig BA. ‘To prove this is the industry's best hope’: Big tobacco's support of research on the genetics of nicotine addiction. Addiction 2010; 105: 974–983
   PubMed Web of Science ®Google Scholar
• Hall W, Capps B, Carter A. The use of depot naltrexone under legal coercion: The case for caution. Addiction 2008; 103: 1922–1924
   PubMed Web of Science ®Google Scholar
• Hall W, Lucke J. Legally coerced treatment for drug using offenders: Ethical and policy issues. Crime and Justice Bulletin 2010; 144: 1–12
   Google Scholar
• Hall W, Madden P, Lynskey M. The genetics of tobacco use: Methods, findings and policy implications. Tobacco Control 2002; 11: 119–124
   PubMed Web of Science ®Google Scholar
• Hall W, Pacula RL. Cannabis use and dependence: Public health and public policy. Cambridge University Press, Cambridge 2003
   Google Scholar
• Hall W, Swift W. The policy implications of cannabis dependence. The nature, consequences, and treatment of cannabis dependence, R Roffman, R Stephens. Cambridge University Press, Cambridge 2006; 315–339
   Google Scholar
• Hall W, Teesson M. Alcohol use disorders: Who should be treated and how?. Unmet need in psychiatry: Problems, resources, responses, G Andrews, A Henderson. Cambridge University Press, Cambridge 1999; 290–301
   Google Scholar
• Hall W, Teesson M, Lynskey M, Degenhardt L. The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: Findings from the National Survey of Mental Health and Well-Being. Addiction 1999; 94: 1541–1550
   PubMed Web of Science ®Google Scholar
• Heyman G. Addiction: A disorder of choice. Harvard University Press, Cambridge, MA 2009
   Google Scholar
• Higgins ST, Bernstein IM, Washio Y, Heil SH, Badger GJ, Skelly JM, Solomon LJ, et al. Effects of smoking cessation with voucher-based contingency management on birth outcomes. Addiction 2010; 105: 2023–2030
   PubMed Web of Science ®Google Scholar
• Hutchison KE. Substance use disorders: Realizing the promise of pharmacogenomics and personalized medicine. Annual Review of Clinical Psychology 2010; 6: 577–589
   PubMed Web of Science ®Google Scholar
• Iversen L. The science of marijuana. Oxford University Press, Oxford 2002
   Google Scholar
• Kahneman D. Thinking, fast and slow. Allen Lane, London 2011
   Google Scholar
• Kalant H. What neurobiology cannot tell us about addiction. Addiction 2010; 105: 780–789
   PubMed Web of Science ®Google Scholar
• Kendler KS, Chen X, Dick D, Maes H, Gillespie N, Neale MC, Riley B. Recent advances in the genetic epidemiology and molecular genetics of substance use disorders. Nature Neuroscience 2012; 15: 181–189
   PubMed Web of Science ®Google Scholar
• Kincaid H, Sullivan JA. Medical models of addiction. What is addiction?, D Ross, H Kincaid, D Spurrett. MIT, Cambridge, MA 2010; 353–376
   Google Scholar
• Kleiman M. Against excess: Towards a drug policy that works. Basic Books, New York 1992
   Google Scholar
• Knapp CM, Tozier L, Pak A, Ciraulo DA, Kornetsky C. Deep brain stimulation of the nucleus accumbens reduces ethanol consumption in rats. Pharmacology, Biochemistry & Behavior 2009; 92: 474–479
   PubMed Web of Science ®Google Scholar
• Koob GF. The neurobiology of addiction: A neuroadaptational view relevant for diagnosis. Addiction 2006; 101 Suppl 1: 23–30
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Neurobiology of addiction. Academic Press, New York 2006
   Google Scholar
• Koob GF, Lloyd GK, Mason BJ. Development of pharmacotherapies for drug addiction: A Rosetta Stone approach. Nature Reviews Drug Discovery 2009; 8: 500–515
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35: 217–238
   PubMed Web of Science ®Google Scholar
• Leshner AI. Addiction is a brain disease, and it matters. Science 1997; 278: 45–47
   PubMed Web of Science ®Google Scholar
• Lewis MJ. The early alcoholism treatment movement in Australia, 1859–1939. Drug and Alcohol Review 1992; 11: 75–84
   PubMedGoogle Scholar
• Lipsman N, Neimat JS, Lozano AM. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: The search for a valid target. Neurosurgery 2007; 61((1))1–11, discussion 11–13
   PubMed Web of Science ®Google Scholar
• Lu L, Wang X, Kosten TR. Stereotactic neurosurgical treatment of drug addiction. American Journal of Drug and Alcohol Abuse 2009; 35: 391–393
   PubMed Web of Science ®Google Scholar
• Luigjes J, Mantione M, van den Brink W, Schuurman PR, van den Munckhof P, Denys D. Deep brain stimulation in addiction: A review of potential brain targets. Molecular Psychiatry 2012; 17: 572–583
   PubMed Web of Science ®Google Scholar
• McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689–1695
   PubMed Web of Science ®Google Scholar
• Midanik L. Biomedicalization of alcohol studies: Methodological shifts and institutional challenges. Transaction Publishers, New Brunswick, NJ 2006
   Google Scholar
• Miller P, Carter A, De Groot F. Investment and vested interests in neuroscience research of addiction: Why research ethics requires more than informed consent. Addiction neuroethics: The ethics of addiction research and treatment, A Carter, W Hall, J Illes. Elseveir, New York 2012; 278–301
   Google Scholar
• Nutt D. Equasy – An overlooked addiction with implications for the current debate on drug harms. Journal of Psychopharmacology 2009; 23: 3–5
   PubMed Web of Science ®Google Scholar
• Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet 2007; 369: 1047–1053
   PubMed Web of Science ®Google Scholar
• Orford J. An unsafe bet: The dangerous rise of gambling and the debate we should be having. John Wiley and Sons, Chichester 2011
   Google Scholar
• Pierce JP, Gilpin EA, Emery SL, White MM, Rosbrook B, Berry CC. Has the California tobacco control program reduced smoking?. JAMA 1998; 280: 893
   PubMed Web of Science ®Google Scholar
• Proctor RN. Golden holocaust: Origins of the cigarette catastrophe and the case for abolition. University of California Press, Los Angeles 2012
   Google Scholar
• Productivity Commission. Gambling, report no. 50. Australian Government, Canberra 2010
   Google Scholar
• Reske M, Paulus MP. A neuroscientific approach to addiction: Ethical issues. Oxford handbook of neuroethics, J Illes, B Sahakian. Oxford University Press, Oxford 2011; 177–202
   Google Scholar
• Robins LN. Vietnam veterans' rapid recovery from heroin addiction: A fluke or normal expectation?. Addiction 1993; 88: 1041–1054
   PubMed Web of Science ®Google Scholar
• Robins LN, Helzer JE, Hesselbrock M, Wish E. Vietnam veterans three years after Vietnam: How our study changed our view of heroin. The American Journal on Addictions 2010; 19: 203–211
   PubMed Web of Science ®Google Scholar
• Room R. Social policy and psychoactive substances. Drugs and the future: Brain science, addiction and society, D Nutt, T Robbins, G Stimson. Academic Press, London 2007; 337–358
   Google Scholar
• Room R, Fischer B, Hall W, Lenton S, Reuter P. Cannabis policy: Moving beyond stalemate. Oxford University Press, Oxford 2010
   Google Scholar
• Rose G. The strategy of preventive medicine. Oxford University Press, Oxford 1992
   Google Scholar
• Rouaud T, Lardeux S, Panayotis N, Paleressompoulle D, Cador M, Baunez C. Reducing the desire for cocaine with subthalamic nucleus deep brain stimulation. Proceedings of the National Academy of Sciences 2010; 107: 1196–1200
   PubMed Web of Science ®Google Scholar
• Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, Sturm V, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 2008; 33: 368–377
   PubMed Web of Science ®Google Scholar
• Servello D, Porta M, Sassi M, Brambilla A, Robertson MM. Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: The surgery and stimulation. Journal of Neurology, Neurosurgery & Psychiatry 2008; 79: 136–142
   PubMed Web of Science ®Google Scholar
• Singh I, Rose N. Biomarkers in psychiatry. Nature 2009; 460: 202–207
   PubMed Web of Science ®Google Scholar
• Stephen JH, Halpern CH, Barrios CJ, Balmuri U, Pisapia JM, Wolf JA, Stein SC, et al. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: A threshold and cost-effectiveness analysis. Addiction 2012; 107: 624–634
   PubMed Web of Science ®Google Scholar
• Sullivan M, Birkmayer F, Boyarsky B, Frances R, Fromson J, Galanter M, Suchinsky R, et al. Uses of coercion in addiction treatment: Clinical aspects. American Journal on Addictions 2008; 17: 36–47
   PubMed Web of Science ®Google Scholar
• Synofzik M, Schlaepfer TE. Stimulating personality: Ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes. Biotechnology Journal 2008; 3: 1511–1520
   PubMedGoogle Scholar
• Szasz TS. Ceremonial chemistry: The ritual persecution of drugs, addicts, and pushers. Routledge, London 1975
   Google Scholar
• Vassoler FM, Schmidt HD, Gerard ME, Famous KR, Ciraulo DA, Kornetsky C, Pierce RC, et al. Deep brain stimulation of the nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug seeking in rats. Journal of Neuroscience 2008; 28: 8735–8739
   PubMed Web of Science ®Google Scholar
• Volkow N, Fowler JS, Wang GJ, Teland F, Baler R. Imaging dopamine's role in drug abuse and addiction. Dopamine handbook, ILS Iversen, S Dunnett, A Bjorklund. Oxford University Press, Oxford 2010; 407–417
   Google Scholar
• Volkow ND, Li TK. Drug addiction: The neurobiology of behaviour gone awry. Nature Reviews Neuroscience 2004; 5: 963–970
   PubMed Web of Science ®Google Scholar
• Vos T, Carter R, Barendregt J, Mihalopoulos C, Veerman L, Magnus A, Wallace A, et al. Assessing cost-effectiveness in prevention: ACE–prevention September 2010 final report. The University of Queensland, Brisbane 2010
   Google Scholar
• Vrecko S. Capital ventures into biology: Biosocial dynamics in the industry and science of gambling. Economy and Society 2008; 37: 50–67
   Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Lang AE, et al. Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Archives of Neurology 2010; 67: 589–595
   PubMed Web of Science ®Google Scholar
• White V, Hill D, Siahpush M, Bobevski I. How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tobacco Control 2003; 12: ii67
   PubMed Web of Science ®Google Scholar